Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial-Reference-Cited by-同舟云学术

Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial

Published:2007-05 Issue:5 Volume:132 Page:1672-1683
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Targan Stephan R.,Feagan Brian G.,Fedorak Richard N.,Lashner Bret A.,Panaccione Remo,Present Daniel H.,Spehlmann Martina E.,Rutgeerts Paul J.,Tulassay Zsolt,Volfova Miroslava,Wolf Douglas C.,Hernandez Chito,Bornstein Jeffrey,Sandborn William J.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference22 articles.

1. The pathophysiologic role of alpha 4 integrins in vivo;Lobb;J Clin Invest,1994

2. A structural view of integrin activation and signaling;Giancotti;Dev Cell,2003

3. a4 Integrins as therapeutic targets in autoimmune disease;von Andrian;N Engl J Med,2003

4. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn’s disease;Gordon;Gastroenterology,2001

5. Natalizumab for active Crohn’s disease;Ghosh;N Engl J Med,2003

Cited by 548 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins;The Korean Journal of Gastroenterology;2024-08-25

2. Initiation of vedolizumab did not provoke new‐onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24‐week study with imaging assessments;United European Gastroenterology Journal;2024-07-04

3. miR-200c-3p regulates α4 integrin-mediated T cell adhesion and migration;Experimental Cell Research;2024-07

4. Lack of mTORC2 signaling in CD11c+ myeloid cells inhibits their migration and ameliorates experimental colitis;Journal of Leukocyte Biology;2024-04-23

5. Update for surgeons on novel induction treatments for acute severe inflammatory bowel disease associated colitis;ANZ Journal of Surgery;2024-03-07